Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 167

1.

Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors.

Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, Ye Y, Wu X, Vierling JM, Beretta L.

Hepatol Commun. 2018 Apr 27;2(6):718-731. doi: 10.1002/hep4.1187. eCollection 2018 Jun.

2.

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC, Vierling JM, Nguyen MH.

BMJ Open Gastroenterol. 2018 May 5;5(1):e000203. doi: 10.1136/bmjgast-2018-000203. eCollection 2018.

3.

Autoimmune hepatitis.

Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ.

Nat Rev Dis Primers. 2018 Apr 12;4:18017. doi: 10.1038/nrdp.2018.17. Review.

PMID:
29644994
4.

Unmet needs and new models for future trials in autoimmune hepatitis.

Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM.

Lancet Gastroenterol Hepatol. 2018 May;3(5):363-370. doi: 10.1016/S2468-1253(18)30043-8. Epub 2018 Apr 6.

PMID:
29644978
5.

Predicting Liver Allograft Discard: The Discard Risk Index.

Rana A, Sigireddi RR, Halazun KJ, Kothare A, Wu MF, Liu H, Kueht ML, Vierling JM, Sussman NL, Mindikoglu AL, Miloh T, Galvan NTN, Cotton RT, O'Mahony CA, Goss JA.

Transplantation. 2018 Sep;102(9):1520-1529. doi: 10.1097/TP.0000000000002151.

PMID:
29485514
6.

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME.

J Clin Oncol. 2018 Feb 15:JCO2017756387. doi: 10.1200/JCO.2017.75.6387. [Epub ahead of print]

PMID:
29447061
7.

Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM.

Dig Dis Sci. 2018 Mar;63(3):665-675. doi: 10.1007/s10620-017-4897-z. Epub 2018 Feb 1.

PMID:
29392554
8.

No Gains in Long-Term Survival After Liver Transplantation Over the Past Three Decades.

Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, Wu MF, Yoeli D, Kueht M, Mindikoglu AL, Sussman NL, Galván NT, Cotton RT, O'Mahony CA, Goss JA.

Ann Surg. 2018 Jan 4. doi: 10.1097/SLA.0000000000002650. [Epub ahead of print]

PMID:
29303806
9.

Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C.

Transl Res. 2018 May;195:25-47. doi: 10.1016/j.trsl.2017.12.002. Epub 2017 Dec 12.

PMID:
29291380
10.

Liver transplant length of stay (LOS) index: A novel predictive score for hospital length of stay following liver transplantation.

Rana A, Witte ED, Halazun KJ, Sood GK, Mindikoglu AL, Sussman NL, Vierling JM, Kueht ML, Galvan NTN, Cotton RT, O'Mahony CA, Goss JA.

Clin Transplant. 2017 Dec;31(12). doi: 10.1111/ctr.13141. Epub 2017 Nov 13.

PMID:
29044759
11.

Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.

Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, Vierling JM, Hirschfield GM.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):278-287.e7. doi: 10.1016/j.cgh.2017.09.062. Epub 2017 Oct 6.

PMID:
28993258
12.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.

PMID:
28818518
13.

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.

PMID:
28802814
14.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.

N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.

15.

A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association?

Goss M, Reese J, Kueht M, Vierling JM, Mindikoglu AL, Sussman NL, Kaplan B, Wood RP, Rana AA.

Liver Transpl. 2017 May;23(5):698-700. doi: 10.1002/lt.24761. No abstract available.

16.

Expert clinical management of autoimmune hepatitis in the real world.

Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG).

Aliment Pharmacol Ther. 2017 Mar;45(5):723-732. doi: 10.1111/apt.13907. Epub 2016 Dec 22.

17.

Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.

Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H.

Hepatol Int. 2016 Nov;10(6):909-915. Epub 2016 Sep 20. Review.

PMID:
27649967
18.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.

Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845.

19.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B.

Gastroenterology. 2017 Jan;152(1):164-175.e4. doi: 10.1053/j.gastro.2016.09.045. Epub 2016 Oct 5.

PMID:
27720838
20.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD.

Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016.

Supplemental Content

Loading ...
Support Center